Is Xilio Therapeutics, Inc. (NASDAQ:XLO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Xilio Therapeutics, Inc. at current levels.
A $58M masked-cytokine bet with a Gilead partnership doing the heavy lifting, three shots on goal, and binary readouts inside 18 months.
Where XLO is headed
The interesting thing about Xilio in mid-2026 is not the pipeline on the slide deck. It is the fact that a clinical-stage immuno-oncology company carrying three tumor-activated assets is trading at $58M, roughly the same as the cash it consumes in 18 months of operations. The market has priced this as a melting ice cube. The cap table says otherwise: the Gilead collaboration on the masked effector program puts a deep-pocketed partner behind the platform, and the vilastobart plus atezolizumab combo in MSS colorectal is the one program where masked CTLA-4 actually has a credible biological reason to work where unmasked CTLA-4 has failed for a decade.
Read the full Compass Direction on XLO
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $8.25).
See the full XLO analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Xilio Therapeutics, Inc. (NASDAQ:XLO) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Xilio Therapeutics, Inc. at current levels. A $58M masked-cytokine bet with a Gilead partnership doing the heavy lifting, three shots on goal, and binary readouts inside 18 months.
What is XLO's Compass Score?
Xilio Therapeutics, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for XLO?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the XLO page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.